Clinical pharmacology provides a valuable opportunity to accelerate the near-term development of existing repurposed drugs for COVID-19 treatment and therapy.Read More
Author: Piet van der Graaf and Kathleen Giacomini
Piet van der Graaf is Senior Vice President Quantitative Systems Pharmacology (QSP) at Certara and Professor of Systems Pharmacology at Leiden University (The Netherlands). He has over 20 years of experience in drug discovery and development working at Pfizer, Synthélabo (Sanofi) and as CSO of the Leiden Academic Centre for Drug Research. He was the founding Editor-in-Chief of CPT: Pharmacometrics & Systems Pharmacology (PSP) before becoming Editor-in-Chief of Clinical Pharmacology & Therapeutics (CPT). He received his doctorate training in quantitative pharmacology and PhD in Clinical Medicine with Nobel laureate Sir James Black at King's College London and his PharmD from the University of Groningen (The Netherlands). He brings his considerable skill and experience to our projects and contributes to the strategic development of Certara. Kathleen Giacomini is Professor of Bioengineering and Therapeutic Sciences at the University of California, San Francisco (USA) She is a leader in the field of membrane transporters with a focus on genetic polymorphisms. Her work ranges from basic to clinical research. For example, she has discovered genetic variants that underlie inter-individual variation in response to the anti-diabetic drug metformin and has recently de-orphaned SLC22A24, an anion exchanger that preferentially transports steroid conjugates. She is co-founder of the International Transporter Consortium, which has published highly impactful papers informing regulatory policy. Currently, she is a co-Principal Investigator of the UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation. She has received numerous awards and is an elected member of the National Academy of Medicine (USA).